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Usher syndrome type IIa (USHIIa) is an autosomal recessive disorder characterized by moderate to severe senso-
rineural hearing loss and progressive retinitis pigmentosa. This disorder maps to human chromosome 1q41.Recently,
mutations in USHIIa patients were identified in a novel gene isolated from this chromosomal region. The USH2A
gene encodes a protein with a predicted molecular weight of 171.5 kD and possesses laminin epidermal growth
factor as well as fibronectin type III domains. These domains are observed in other protein components of the
basal lamina and extracellular matrixes; they may also be observed in cell-adhesion molecules. The intron/exon
organization of the gene whose protein we name “Usherin” was determined by direct sequencing of PCR products
and cloned genomic DNA with cDNA-specific primers. The gene is encoded by 21 exons and spans a minimum
of 105 kb. A mutation search of 57 independent USHIIa probands was performed with a combination of direct
sequencing and heteroduplex analysis of PCR-amplified exons. Fifteen new mutations were found. Of 114 inde-
pendent USH2A alleles, 58 harbored probable pathologic mutations. Ten cases of USHIIa were true homozygotes
and 10 were compound heterozygotes; 18 heterozygotes with only one identifiable mutation were observed. Sixty-
five percent (38/58) of cases had at least one mutation, and 51% (58/114) of the total number of possible mutations
were identified. The allele 2299delG (previously reported as 2314delG) was the most frequent mutant allele observed
(16%; 31/192). Three new missense mutations (C319Y, N346H, and C419F) were discovered; all were restricted
to the previously unreported laminin domain VI region of Usherin. The possible significance of this domain, known
to be necessary for laminin network assembly, is discussed in the context of domain VI mutations from other
proteins.
Introduction
Usher syndrome (MIM 276900), an autosomal recessive
disorder characterized by moderate to profound senso-
rineural hearing loss and retinitis pigmentosa (RP), is the
most frequent cause of combined deafness and blindness
in the industrialized world. The incidence of Usher syn-
drome in the United States is estimated at 4.4/100,000
(Boughman et al. 1983). The syndrome is both clinically
and genetically heterogeneous and has been divided into
three clinical subtypes, types I, II (MIM 276901), and
III (MIM 276902; Smith et al. 1994). The subtypes differ
in the degree of hearing loss and in the presence or ab-
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sence of vestibular abnormalities. Usher type I patients
are profoundly deaf and have absent vestibular re-
sponses, whereas Usher type II patients suffer frommod-
erate to severe hearing loss and have normal vestibular
responses. Usher type III patients exhibit progressive
hearing loss and variable vestibular abnormalities. In all
forms of Usher syndrome, the hearing loss is accom-
panied by progressive RP.
At present, 10 distinct genetic loci have been identi-
fied for the three clinical Usher phenotypes: 6 loci cor-
respond to the Usher type I phenotype, 3 for the Usher
type II phenotype, and 1 for Usher type III (Kimberling
et al. 1990; Kaplan et al. 1992; Kimberling and Smith
1992; Smith et al. 1992; Keats et al. 1994; Sankila et
al. 1995; Wayne et al. 1996, 1997; Chaib et al. 1997;
Hmani et al. 1999; Pieke-Dahl et al., in press). Although
it was originally believed that the Usher syndrome type
I phenotype was the most common form of Usher syn-
drome, our experience is that the Usher type II phe-
notype accounts for more than half of Usher cases.Most
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Usher type II families show linkage to the type IIa locus
on 1q41, and the gene responsible for Usher syndrome
type IIa (USH2A) has recently been identified (Eudy et
al. 1998). Although the function of the protein (named
“Usherin”) is unknown, Usherin has a predicted mo-
lecular weight of 171.5 kD and has significant sequence
similarity to a number of extracellular matrix proteins
and receptors containing laminin-like epidermal growth
factor and fibronectin type III repeats.
A comprehensive mutation-detection strategy for dif-
ferential diagnosis of patients with Usher syndrome re-
quires knowledge of the genomic organization of the
USH2a gene, USH2A. In this report we describe the
intron/exon genomic organization and sequence of the
USH2A gene, from which a set of 21 primer pairs suit-
able for mutation testing was developed. Heteroduplex
and direct sequencing analyses of the DNA from 57
independent USHIIa patients were performed to de-
termine the frequency and distribution of USH2A
mutations.
Methods
Genomic Structure
To identify and isolate bacterial artificial chromo-
somes (BACs) containing the USH2A gene, BAC librar-
ies from Genome Systems and Research Genetics were
screened with PCR by use of primer pairs from the crit-
ical region of the USH2A gene; these were listed in the
database maintained by the Whitehead Institute for
Biomedical Research/MIT Center for Genome Research.
We obtained additional sequence-tagged sites by se-
quencing the ends of the BACs obtained from the initial
BAC library screening.
PCR Conditions
Oligonucleotide primers were designed from the con-
sensus sequence of the USH2A cDNA sequence and used
for PCR and cycle-sequencing reactions. BAC clones
were grown in 100 ml of Luria-Bertani broth supple-
mented with 12.5 mg/ml chloramphenicol overnight and
purified with Qiagen tip 100 columns. Human genomic
DNA was isolated from whole blood with a Puregene
kit (Gentra Systems).
Primer combinations for PCR reactions withTaqGold
(Perkin Elmer) or Elongase (Gibco-BRL) were tested
with human genomic DNA and BAC clones as tem-
plates. PCR reactions were as follows: 10 ng BAC or
200 ng human genomic DNA, 1# reaction buffer, 0.2
mM each dNTP, 2.0 mM MgCl2, 0.2 mM each primer;
95C for 10 min followed by 37 cycles of 95C for 30
s, 55C for 30 s, and 72C for 2 min. Elongase enzyme
reactions were as follows: 10 ng BAC or 200 ng human
genomic DNA, 1# reaction buffer, 0.2 mM each dNTP,
1.5 mM or 2.0 mM MgCl2, 0.2 mM each primer for
genomic templates, and 0.4 mM each primer for BAC
templates; 94C for 30 s followed by 35 cycles of 94C
for 30 s, 55C for 30 s, and 72C for 10 min.
DNA Sequencing
PCR products were purified and concentrated prior
to sequencing by Microcon 100 filters (Ambion). ABI
Prism BigDye Terminator Cycle Sequencing Ready Re-
action kits (Perkin Elmer) were used to generate se-
quence from both purified PCR products and BACDNA
templates. PCR products were sequenced with 4 pmol
Usherin-specific primers and 4 ml ready-reaction mix in
a total volume of 10 ml for 25 cycles of 95C for 10 s,
50C for 5 s, and 60C for 4 min. BAC DNA (500 ng–
2 mg) was sequenced in 20-ml reaction volumes by 30
pmol of SP6, T7 pBELOBAC11 vector primers or
USH2A primers, 8 ml ready-reaction mix in a total vol-
ume of 20 ml for 95C for 5 min followed by 99 cycles
of 95C for 20 s, 55C for 30 s, and 60C for 4 min.
Sequencing reactions were precipitated and resuspended
in a 5:1 ratio of formamide/dye loading buffer (6 ml for
PCR products and 2 ml for BAC DNA). Two microliters
were loaded onto 4.8% (36-cM plates) or 5.25% (48-
cM plates) PAGE-PLUS (Amresco) sequencing gels and
run on the ABI Prism model 377 DNA sequencer ac-
cording to ABI protocols. Sample files were generated
from gel files by ABI Sequencing Analysis 3.0. Fractura
2.0 (ABI) was used to remove vector and ambiguous
sequences. Contig assembly was performed by the AU-
TOASSEMBLER program (ABI).
Mutation Screening
Table 1 lists the intronic primers used in this study
and the amplification sizes of their PCR products sur-
veyed for mutations. A set of 95 anonymous control
DNA samples was also screened to assess the frequency
of USH2A mutations in a population unaffected by
USHIIA.
Heteroduplex Analysis
PCR products amplified from samples taken from
USHIIa probands and cloned control DNA were mixed,
heated at 95C for 3 min, and cooled to 25C over a
45-min period. The reannealed reaction products were
then electrophoresed through 35 cm# 43 cm# 1 mm
1# MDE (FMC) at 850 V for 18–24 h, stained with
1 mg/ml ethidium bromide, and visualized under ultra-
violet light. Mixing with control PCR DNA prior to
heteroduplex formation was done to allow detection of
both homozygous and heterozygous mutations.
Direct Link Sequencing
Five-microliter PCR products were treated with 10 U
of shrimp alkaline phosphatase (SAP; Amersham) for 30
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Table 1
USH2A Primers Used in Mutation Analysis of 57 USHIIa
Patients
Primer
Set Primer Sequence
Exon
Ampli-
fied
PCR
Size
(bp)
Exon1U AATGGATTGAGGTGCATGAG 1 525
Exon1L ACCCAACACCATCTGTCTGT
Exon2U GCCTGGGATGAGCTTCAG 2 840
Exon2L GGTTTGGAATTCAGGCTGA
Exon3U CACCACTGTAACTGCACAATACC 3 344
Exon3L CTGCTGCAGATTTTGTGAGTAGA
Exon4U GTCTTCCCAGCTGAACAAAGTA 4 375
Exon4L GTGGTAATTTGTTCAGTAGCCCTAG
Exon5U GTCAGGTATTGCTTGGTAAACAG 5 173
Exon5L CAGCATTTATCCTTTCGGTTC
Exon6U TGACATTCATTTGTAACGACTCC 6 442
Exon6L AAGTTTGTGGGCATTTGTTG
Exon7U CCATGGTTTGATATATACTGATGG 7 336
Exon7L CACCAGCCTAGAGAGCTAGC
Exon8U CAACATTTTGATTTCTGTTTTGC 8 370
Exon8L TGCTCTGACATCTTAATGTGCT
Exon9U CACACAATGCATATAGTCCTAGG 9 267
Exon9L TGTTAGGCCAAGATTAAGTTCAT
Exon10U TGATATGTGCTTTACTTCTGGTG 10 356
Exon10L GCATTGTAGATAGAAGCACACAG
Exon11U TGGCAGGTAGAGATGAAAGG 11 371
Exon11L GCAAATGCAGTCTTCAATTCTAC
Exon12U CCCTGTCTTGTACCTAATGAGC 12 323
Exon12L TTCCAGATGGTAATAGAGATGTGA
Exon13U GCAGTAGCATTGTTTGTGTCTC 13 816
Exon13L GTAGAAGCCACAAACCAGAAAC
Exon14U GGGAATTAGTGCCTTGGTAGAG 14 379
Exon14L GAAGTTATTGCTTTGCAACTGC
Exon15U AAGCCGTCTTACTCTACAATGCT 15 360
Exon15L TTCTGATGGGTTCTAAATGGAG
Exon16U GCAATCCTGAATCAGAAAGACC 16 354
Exon16L CCACAACAGCATTTATCCTCAA
Exon17U GAGAGGAAAGCAGTTAGCAATG 17 626
Exon17L GATTCTCATTCATGTCTTGACCA
Exon18U AAGTAACCCCTTTGTCTGATGAGT 18 378
Exon18L GGAAACATTTGCATTCAGAGG
Exon19U TCAGAAACTAAATGAATGTGTGA 19 379
Exon19L TGCCCTGTTTAATCAATATAGAG
Exon20U TGGTGGTTGGCAATAATTCC 20 381
Exon20L GAGTTAGTGAGGGAGGAGAAGACA
Exon21U AGCCATACAGATACTTGAAACC 21 501
Exon21L GCTATCAAAGGGCTGAATTAG
min at 37C, and the enzyme was inactivated at 80C
for 15 min. SAP was used to dephosphorylate unincor-
porated dNTPs prior to cycle sequencing. Sequencing
reactions contained 2.8 ml of the BigDye Terminator
Cycle Sequencing Ready Reaction mix (Perkin Elmer),
2.5 ml SAP-treated PCR product, and 20 pmol primer.
Cycling conditions were 30 cycles of 95C for 10 s, 55C
for 5 s, and 60C for 4 min. Sequencing reactions were
precipitated in 60% ethyl alcohol (final), dried, and re-
suspended in 4 ml of a 5:1 ratio of formamide/loading
dye. One microliter was loaded onto 4.8% PAGE-
PLUS (Amresco) 36-cm sequencing gels and run on
the ABI Prism model 377 DNA sequencer according to
ABI protocols. Sample files were generated from gel files
by ABI Sequencing Analysis 3.3. The Fractura 2.2 pro-
gram was used to remove ambiguous sequences and
identify heterozygous base positions. Sequence datawere
aligned and analyzed for mutations by Sequence Navi-
gator 1.0.1.
Comparative Analysis
A total of 32 proteins bearing laminin domain VI mo-
tifs were used to evaluate the functional significance of
the three missense mutations found within domain VI
of Usherin (see fig. 4 below). The first 300 amino acids
from each of these protein sequences were compared
with amino acids 250–550 of the Usherin protein by a
progressive pairwise alignment strategy by the MULTI-
ALIGN program (Poˆle Bio-Informatique Lyonnais; Cor-
pet 1988).
Results
Genomic Structure
Figure 1 presents an ∼325-kb contig assembly across
the region that contains the human USH2A gene. Am-
plification products produced by Elongase by primers
specific for both USH2A cDNA and BAC DNA corre-
sponded to seven fragments containing the following
exons with their intervening introns: 1–3, 5–8, 10–11,
12–13, 17–18, 18–19, and 19–20. The intron sizes were
estimated by agarose gel electrophoresis or were se-
quenced (IVS1, -6, -7, and -17). Attempts to amplify the
following introns were unsuccessful: 3, 4, 8, 9, 11, 13,
14, 15, 16, and 20. Intron/exon boundaries were deter-
mined initially by manual inspection of sequence data,
then confirmed by direct sequencing of PCR products
from BAC DNA by USH2A cDNA primers. The initial
determination of intron/exon boundaries was bymanual
inspection of sequence data. All boundaries were found
to be consistent with the invariant intronic AG and GT
features that flank the beginning and end of the majority
of vertebrate exons, respectively. The contig assembly
program AUTOASSEMBLER (ABI) was used on all se-
quence data generated. Seventeen separate sequence con-
tigs from an input of 174 sequence files were generated
and used to confirm the genomic organization. The total
length of the 17 contigs was 33.6 kb.
The Usherin gene is encoded by 21 exons (fig. 1). Table
2 lists the sizes and starting positions of each of the 21
exons, the surrounding intronic sequence, intron sizes
(where known), and GenBank accession numbers from
the National Center for Biotechnology Information. Re-
liable genomic sequence extends 667 nt 5′ from the start
of the cDNA sequence. The last genomic contig extends
605 bp 3′ from the published end of USH2A.
A significant sequence difference between the pub-
lished cDNA and genomic DNA concerns the ATG
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Figure 1 BAC/PAC contig of the USH2A critical region on chromosome 1q41 developed from the use of sequence tagged sites and
expressed sequence tags from the region (see Results section). The location and orientation of the 21 USH2A exons within the contig is shown.
Those portions of the gene that are not shaded black are untranslated, as predicted from the cDNA sequence.
translation start site. A stretch of five thymidines was
previously observed to start at cDNA position 5 rel-
ative to the ATG start site; this was found to be six
thymidines on all other genomic-based templates. The
additional thymidine removes five amino acids from the
beginning of the cDNA’s longest open-reading frame
(fig. 2A). A reexamination of the USH2A cDNA primary
sequence data for this region revealed that the cDNA
does contain six thymidines, in complete agreement with
the genomic sequence. The poly-A tail of the cDNA se-
quence corresponds to a 20-nt imperfect poly-A stretch
interrupted by 2 Gs in the genomic sequence (fig. 2B).
It is likely that the true 3′ end occurs downstream of this
imperfect poly-A feature. A potential polyadenylation
signal (aataaa) was found 340 nucleotides 3′ from the
end of the poly-A feature. The SignalP program (SignalP
V1.1 World Wide Web Prediction Server, Center for Bi-
ological Sequence Analysis) predicted that the first 31
aa of Usherin would be a eukaryotic signal peptide (Niel-
sen et al. 1997). Therefore, the change in primary struc-
ture of Usherin from that previously reported (Eudy et
al. 1998) does not alter the predicted role of this motif
as a signal peptide for potential transport into the ex-
tracellular space. The sequence difference reduces the
total length of the Usherin protein from 1551 to 1546
amino acids and results in a change of nomenclature for
reported mutations; thus, the 2314delG (E772FS) mu-
tation that we previously reported has become 2299delG
(E767FS).
Mutations
Table 1 provides the primers, designed from intronic
sequence, that were used in the mutation testing we de-
scribe here. Exons 1, 2, 5, 13, 17, and 21 were surveyed
for mutations by direct sequencing. Exons 3, 14, 16, and
19 were screened by heteroduplex analysis, and heter-
oduplex-positive samples were sequenced to identify the
mutation. To compare the sensitivity of the twomethods
for the detection of USH2A mutations, exons 4, 6–12,
15, 18, and 20 were screened by both methods.
Seven sequence changes—373ArG, 802GrA,
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Table 2
Intron/Exon Boundaries for the 21 Exons of the Usherin Gene
Exon
Exon
Length cDNA Start 5′ Acceptor Slice Site 3′ Donor Splice Site
GenBank
Accession
Number
Intron
Length IVS
1 182 1 Not applicable aagaaatggtaactcagcttattt AF091873 673 bp 1
2 688 183 cgtttttgattcccagATACCAGC GGTGTAATgtaagtagtagtgtag AF091873 ∼3 kb 2
3 166 871 ccggttgcttcctaagGTGTGTTA GTGTGCAGgtgagtaaaataaaaa AF091874 ) 3
4 133 1037 tggtaatttcttacagGTGCATCA TTTAAATGgtaagtttctgacttc AF091875 ) 4
5 64 1170 atgtgtgtatttgcagGTTTAGAG ACAAACAGgtaagcagatgttgca AF091876 ∼2.1 kb 5
6 295 1234 ctcttgactcccacagAGAGATTC AGTATCAGgtaatgagaaacgata AF091877 952 bp 6
7 185 1529 aactttccattttcagGTGTTTTA CTTTCCAAgtatgaatatttttaa AF091877 472 bp 7
8 222 1714 tttctttcattaacagTTTTACTC AGTGGGAGgtattattatgaattt AF091877 ) 8
9 94 1936 atgctcatgtttgcagATGTCAGT GACTTCATgtgagttctattttat AF091878 ) 9
10 196 2030 atattttttgttctagTGTGATCG CACTACAGgtaagtagcaaataaa AF091879 ∼2.8 kb 10
11 131 2226 cctttccctgatgcagGAAGGAAC GTGATCAGgtgagtttttctgagt AF091880 ) 11
12 196 2357 gttgtatcttctctagATTGGAGG CGTTATTGgtacgtgtaacgcaaa AF091881 ∼3 kb 12
13 642 2553 tatattttatctttagGGCTTAGG TCAACCAGgtaagaaagaaatgta AF091882 ) 13
14 184 3195 atttctttatttctagGTTTTTAT ACTGGAAGgtacatctttataagc AF091883 ) 14
15 164 3379 tttgccttgttttcagATGTCAGC CAGCAAAAgtaagtgaactctggt AF091884 ) 15
16 159 3543 cttcattgtaatttagCTCCATTC CCCATACAgtgagtttaagggttt AF091885 ) 16
17 495 3702 tttcttttcatttcagGTATTCAA ACTAAATGgtaagaatccaaggct AF091886 1,045 bp 17
18 270 4197 tatttaatgtctctagGAATAATT AGAATCAGgtaaagatcaatgttt AF091886 ∼2 kb 18
19 170 4467 ttgttctcattgatagCACCTGTA TTTCACAGgtattgttatttttaa AF091887 ∼6 kb 19
20 145 4637 cttttttgccttgaagCTGTTGCA AGCAGCAGgtaagcaagttttaat AF091888 ) 20
21 1531 4782 gttttctaatatttagCACCAGCA Not applicable AF091889 )
779TrG, 3883CrT, IVS1535ArG, 4510–4511insA,
and 4457ArG—were found by sequence analysis.
Twenty-four sequence changes were observed first by
heteroduplex analysis. In instances where PCR DNA
was subjected to both heteroduplex analysis and se-
quencing, the detection rate for heteroduplex analysis
was 92% of that of direct sequencing. Heteroduplex
analysis did not detect any mutations not observed by
direct sequencing. Thus, direct sequencing is more sen-
sitive than the heteroduplex method at picking up
mutations.
Table 3 lists 31 different nucleotide changes that were
observed in this sample and gives their frequencies in
the patients with Usher II and unaffected control pa-
tients; table 3 also identifies the restriction enzymes that
we used to verify the base changes. The frequency of
USH2A mutations detected is 58 of 114 USH2A alleles
(51%). The number of USHIIa cases homozygous for
mutations is 10, the number of compound heterozygotes
is 10, and the number of cases with only one identified
mutant allele is 18. USH2A mutations were not detected
in 19 patients with Usher II. These proportions lead us
to estimate that we have detected 69% of the true
USH2A mutations and that 4 of the 19 individuals with
no observed mutation harbor a change in USH2A that
remains to be identified. This further leads us to conclude
that ∼26% (15/57) of the families with USH2A in this
sample are not linked to USH2A. This value corresponds
well with an estimate, obtained by heterogeneity analysis
of linkage marker data (Pieke-Dahl et al. 1997) 18% of
cases are not linked to 1q41.
The locations of the 17 pathologic mutations on a
motif-based map of the Usherin protein are summarized
in figure 3. The protein has one laminin type VI domain,
10 laminin-like epidermal growth factor domains, and
four fibronectin type III domains. It is of interest that
the three probable pathologic missense mutations are
limited to the domain VI region. All the other pathologic
mutations we observed produced nonsense codons,
frame shifts of mRNA translation, or splice mutations.
Nonsense Mutations
Seven stop mutations distributed throughout the Ush-
erin gene were observed. None were observed in the
series of 95 controls. All individuals had a typical type
II phenotype.
The 779TrG (L260X) mutation was observed in a
Swedish type II family as a compound heterozygote with
the 2299delG mutation discussed below. A GrA tran-
sition was seen at bp 1227 in exon 7 (W409X) in two
apparently unrelated Dutch families, one homozygous
and the other a compound heterozygote with 1256GrT
(C419F). In exon 10, a 1696CrT (Q566X) mutation
was observed in one Swedish family as a heterozygote.
A 1876CrT (R626X)mutation in exon 11was observed
in an American family of mixed northern European
ancestry that also carried a 2299del mutation. The
2541CrA (C847X) mutation in exon 13 was observed
with the 2299delG allele as a compound heterozygote
in an American family with African heritage. There were
two stop mutations in exon 18; one is an unusual double
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Figure 2 Significant sequence differences between the previously reported cDNA (GenBank accession number AF055580) and genomic
DNA (GenBank accession numbers AF091873 and AF091889) at the 5′ and 3′ ends of the Usherin gene. A, The genomic structure predicts a
start methionine five codons downstream from the ATG predicted by the published cDNA sequence because of an insertion of a T residue. A
reexamination of the primary cDNA sequence data agrees with the genomic DNA data. This predicts a 1546-aa protein. B, At the 3′ end of
the gene, a potential polyadenylation signal (aataaa) was found 340 nt 3′ from the end of a 20-nt imperfect poly-A region found in the genomic
sequence that otherwise lines up with the end of the USH2A cDNA.
transversion 3840-41GArCT (MR1280IX), and the
other is 3883CrT (R1295X). The double transversion
occurred in an American family with European ancestry.
R1295X was seen in the heterozygous state in one sib-
ship of a large Swedish family with three involved sib-
ships; for both families, the companion mutation was
not detected.
Frameshift Mutations
Five mutations cause frameshifts with premature ter-
mination. The first, a four-base insertion in exon 6, 921-
922insCAGC (H308FS), was observed in two com-
pound heterozygotes. The families were reportedly
unrelated, but both were of English-Scottish ancestry.
One family segregated the 2299delG mutation on the
other allele; the other inherited a novel 2052ArG
(Q684Q) maternal allele that could create a possible
cryptic splice acceptor site 81 nt 3′ of the normal splice
acceptor site inside exon 12. One additional 2052ArG
allele from an unrelated USHIIa patient was observed;
this mutation was not observed in any of the 95 control
samples by heteroduplex analysis. A 1679delC (P560FS)
mutation occurred in combination with 2299delG in an
individual who has mixed northern European ancestry.
One consanguineous individual from Venezuela was ho-
mozygous for 2898delG (T967FS), causing a frameshift
starting at codon 967. A deletion of 2 bp, 4338-9delCT
(Q1447FS), was observed in a French Acadian family
with a well-documented Usher II phenotype. Although
the parents of the affected children are believed to be
distantly related, the children are predicted to be com-
pound heterozygote, with the companion mutation still
undetected.
The most common Usherin mutation was 2299delG
(E767FS). We have observed this mutation in 31 of 192
alleles. The increase in the total number of patients tested
for this mutation as well as portions of exons 12, 13,
14, and 20 is due to our previous work (Eudy et al.
1998). This mutation occurred among USHIIa patients
with a variety of ancestries, but all were European. The
single exception was the 2299delG/C840X compound
heterozygote with African heritage, discussed above.
Splicing Mutations
To evaluate the 2052ArG (Q684Q) mutation, we
used the FITCONSENSUS program from the GCG
package to calculate quality scores for the authentic exon
12 acceptor site and the potential cryptic site created by
the mutation with the eukaryotic 3′ splice acceptor con-
sensus table (Mount 1982). The normal splice site qual-
ity score was 42.89; the Q684Q mutation score was
42.28. This mutation was absent from the 95 control
samples; however, its potential to produce aberrant
splice products has not been tested by reverse transcrip-
tase–PCR methods. The other nonpathologic alterations
from table 3, namely 2109TrC (D703D) and 4371GrA
(S1457S), were also checked for potential splicing effects
by FITCONSENSUS. No significant changes in the qual-
ity scores for the natural splice sites in these exons was
observed. The 4371GrA does creates a new AG site in
exon 20, but the quality score calculated from FIT-
CONSENSUS at this potential cryptic acceptor site was
37.67, well below that of the natural site (44.28). In
addition, restriction digests of PCR products from the
95 normal controls indicated that 2109TrC and
4371GrA are both present (table 3).
Missense Mutations
Seven different amino acid changes were observed in
the sample groups. Three of these, 373ArG (T125A),
1931ArT (D644V), and 4457ArG (K1486R), are
clearly polymorphic, as indicated on the basis of their
frequency in the USHIIa population or the normal con-
trols (table 3). In addition, both alleles of the 373ArG
polymorphism were observed from BAC clone sequences
of exon 2. The 802GrA (G268R) change was observed
in a Swedish family in which inheritance of the gene was
maternal. We were not able to test for the presence of
Table 3
DNA Sequence Changes in USH2A
Exon Base Change Codon Change
Frequency in
USH2A Patients
Family
Origin
Frequency
in Controlsa Predicted Pathology
Restriction
Enzymeb
DNA sequence changes in Usherin believed
not to be pathologic:
2 c.373ArG T125A 27/94 ) )c None )
4 IVS3-80TrC ) 9/94 ) 14/190 ? MseI = N
5 c.802GrA G268R 1/94 ) ? )
7 IVS736-39del gatt ) 11/94d ) 14/190 ? BsrI = Y
8 c.1419CrT T473T 22/94 ) ) None )
9 IVS934CrA ) 34/94 ) ) None )
11 c.1931ArT D644V 11/94d ) 18/190 None MaeIII = Y
12 c.2109TrC D703D 1/94 ) 3/188 ? FokI = N
14 c.2880TrC N960N 1/192e ) 0/190 ? )
15 IVS1535ArG ) 38/94 ) ) None )
18 IVS17-8TrG ) 25/94 ) )c None )
18 c.3945CrT N1315N 5/94 ) 2/190 ? NsiI = N
20 c.4371GrA S1457S 4/94 ) 3/188 ? Eco57I = Y
21 c.4457ArG K1486R 35/94 ) 76/188 None AflII = N
Probable pathologic mutations
in Usherin:
4 c.779TrG L260X 1/94 Swedish ) Nonsense )
6 c.921-922insCAGC H308FS 2/94 American ) Frameshift )
6 c.956GrA C319Y 2/94 American 0/190 Missense BsmI = N
6 c.1042ArC N346H 2/94 Swedish, American 0/190 Missense MlnI = Y
7 c.1227GrA W409X 3/94 Dutch ) Nonsense )
7 c.1256GrT C419F 5/94d Dutch 0/190 Missense ApoI = Y
10 c.1679delC P560FS 1/94 American ) Frameshift )
10 c.1696CrT Q566X 1/94 Swedish ) Nonsense MseI = Y
11 c.1876CrT R626X 1/94 American ) Nonsense )
12 c.2052ArG Q684Q 2/192e American 0/190 Cryptic splicing )
13 c.2299delG E767FS 31/192e Many 0/190 Frameshift )
13 c.2541CrA C847X 1/94 American ) Nonsense )
14 c.2898delG T967FS 2/192e Spanish 0/190 Frameshift )
18 c.3840-41GArCT MR1280IX 1/94 American ) Nonsense )
18 c.3883CrT R1295X 1/94 Swedish ) Nonsense )
20 c.4338-9delCT C1447FS 1/192e American 0/190 Frameshift )
21 c.4510-4511insA R1504FS 1/94 American ) Frameshift )
NOTE.—An ellipsis ()) = not applicable; a question mark (?) = unknown.
a A plate of 95 normal controls was screened for the presence of the mutation.
b If the restriction enzyme equals Y, the enzyme will cleave the rarer variant. If N, the enzyme will cleave the common allele.
c These polymorphisms were identified from the sequences of various BAC clones.
d These changes were observed in cis (disequilibrium) within the USHIIa group.
e Portions of exons 12, 13, 14, and 20 were originally screened by heteroduplex analysis in 96 USHIIa and 95 control samples (Eudy et al. 1998).
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Figure 3 Linear structure of Usherin showing the significant domains. The protein has one laminin type VI domain, 10 laminin-like
epidermal growth factor domains, and four fibronectin type III domains. Numbers below the figure are amino acid positions for each motif.
The relative locations of 17 pathologic mutations from an analysis of 57 individuals with USHIIa are shown above the figure. Three missense
mutations, all within domain VI, were discovered. Q684Q creates a punitive cryptic 5′ splice acceptor site. The other mutations produce frame
shifts of mRNA translation or encode nonsense codons.
G268R in the control samples, because this change did
not produce a heteroduplex pattern and no restriction
sites were altered by it. However, exon 5 DNA sequence
from amplified gorilla DNA was homozygous for the
rare human variant (unpublished observations), and so
this base change is not considered likely to be pathologic.
The three missense mutations in USH2A, 956GrA
(C319Y), 1042ArC (N346H), and 1256GrT (C419F)
(fig. 3), all are located within domain VI and are absent
from 95 control samples (fig. 3). The first, C319Y, was
observed to be homozygous in the proband of aHispanic
American family with no family history of consanguin-
ity. N346H was observed in the same large Swedish fam-
ily described above that segregated 1295X. The N346H
mutation was also observed in an American family as a
compound heterozygote with 2299delG. The C419F
mutation was observed exclusively in five Dutch fami-
lies. Three of five Dutch families were simple hetero-
zygotes, two were compound heterozygotes, and one
carried 2299delG and the other W409X.
To evaluate the potential impact of these substitutions
on the Usherin protein, a multiple sequence alignment
was generated by 32 protein sequences with type VI
domains, to identify conserved residues. A portion of
the aligned set of laminin type VI globular domains from
representative proteins and the locations of the three
Usherin missense mutations is shown in figure 4. The
C319Y and C419F mutations involve cysteine residues
absolutely conserved in the type VI domains of these
proteins. The N346H mutation occurs at a noncon-
served residue, but the alignment identity of the aspar-
agine residue with human laminin g1, Caenorhabditis
elegans laminin-like protein-1, human netrin-1, and C.
elegans UNC6 suggests that this residue is also func-
tionally conserved.
Disequilibrium
A 1931ArT polymorphism causes a nonconservative
amino acid change, D644V, in the third laminin-like epi-
dermal growth factor (L-EGF) domain of Usherin. The
polymorphism was observed in the USH2a population
as two D644V homozygotes and seven D644V hetero-
zygotes, for a gene frequency of .096. In the control
population, one homozygote and 16 heterozygotes were
found, resulting in a gene frequency of .094. The C419F
mutation appears to be in disequilibrium with D644V,
because all five Dutch C419F alleles carried in cis the
rarer D644V allele. None of the 95 control samples car-
ried the C419F mutation, as determined by digestion of
exon 7 PCR products with ApoI. Another sequence var-
iant, IVS736-39delGATT, was observed to be in com-
plete disequilibrium with all the USH2a patients who
have the D644V allele. Unfortunately, we were unable
to find USH2A mutations segregating with the 6
IVS736-39delGATT/D644V alleles in USH2a patients
who did not have the C419F mutation. Concerning the
IVS736-39delGATT allele among the control group
with the D644V allele, BsrI digests of exon 7 PCR prod-
ucts showed that 4 of 16 D644V heterozygotes do not
carry an IVS736-39delGATT allele, and the one nor-
mal control D644V homozygote was heterozygous for
IVS736-39delGATT.
Discussion
Knowledge of the gene structure of USH2A was a pre-
requisite before a thorough screening of USHIIa patients
for mutations in that gene could be undertaken. A full
description of the genomic organization of the Usherin
gene will facilitate the screening for additional patho-
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Figure 4 A portion of an aligned set of laminin domain VI regions from representative proteins for the evaluation of three Usherin
missense mutations. The MULTIALIGN program generated a multiple alignment by use of 32 different domain VI–containing sequences with
a progressive pairwise alignment strategy (Corpet 1988). Twenty sequences, representing the three classes of domain VI–bearing laminin subunits
(a, b, and g) and netrins were chosen for display in this figure. Protein name and amino acid numbering are to the left of the lineup, and
GenBank or SwissProt accession numbers are to the right. Included at the bottom of the protein lineup are the locations of relevant mutations
(see Discussion section) within domain VI of UNC-6 (ev437, rh46, and ev436hs), LAMB3 (E210K), LAMA1 (dy2j), and Usherin (C319Y,
N346H, and C419F, in bold). The locations of netrin-specific cysteines are shown by arrows (Wadsworth et al. 1996). Dark-shaded residues
are 190% conserved in all 32 aligned sequences. Light-shaded residues are conserved 50%–90% in all 32 aligned sequences. Both the C319Y
and C419F mutations involve cysteine residues absolutely conserved in the type VI domains of these proteins. The N346H mutation occurs at
a nonconserved residue. Note, however, the alignment identity of the asparagine residue with LMG1_HUMAN, LML1_CAEEL, and all examples
of netrin proteins with the exception of NET3_MOUSE.
logic mutations in patients and families that have
USHIIa. The distribution of mutations across the gene
might suggest certain alternatives for more-expedient
clinical testing. To date, 17 mutations have been iden-
tified (fig. 3).
Combined 2299delG homozygotes and heterozygotes
account for ∼20% of all USHIIa patients and may be
the most frequent mutation causing RP in the human
population. Thus, a reasonable first pass for USHIIa
molecular diagnosis can be made by testing for the
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presence of the 2299delG mutation. The occurrence of
apparent disequilibrium with rare polymorphisms
(D644V, IVS736-39delgatt) suggests that other as-yet-
undetected mutations may also be relatively common.
Usher syndrome is highly heterogeneous, with three
different clinical types and at least 10 different genes.
Usher type II has three subtypes: USHIIa on chromo-
some 1q is due to mutations in the Usherin gene, USHIIb
on chromosome 3p (Hmani et al. 1999), USHIIc on
chromosome 5q (Pieke-Dahl et al., in press), and a
fourth group of Usher II families, affected members of
which have a gene that remains to be localized (data
not shown). The non-USHIIa families are in a minority,
probably accounting for !30% of all cases of Usher II.
This presents a problem for the positional cloning of
the USH2B and USH2C genes. However, screening of
Usher II patients for mutations in Usherin can help in
differentiating those attributable to USH2A from those
attributable to USH2B or USH2C, thus reducing the
impact of heterogeneity on the search for those two
genes. However, it is important to know how thor-
oughly USH2A mutations are detected. Our results in-
dicate that ∼69% of all the true USH2A mutations have
been detected by the methods used in this study.
The interfamilial variation of both the severity of
hearing loss and the onset of RP in individuals with
documented USHIIa may turn out to be due to partic-
ular mutations. Although no clear phenotypic variation
can be assigned to the particular mutations presented
here, a recent study of the prevalence of the 2299delG
mutation included 10 atypical Usher cases and revealed
a surprisingly high 40% carrier frequency, which in-
dicates that environmental or genetic factors influence
the effect of Usherin mutations (Liu et al. 1999).
The delineation of mutations involved in diseases pro-
vide an invaluable resource for identification of regions
of the protein critical to its proper function. This strat-
egy is especially useful with a novel protein such as
Usherin, the function of which can only be speculated
on at this stage of our knowledge. The discovery of
three putative missense mutations (C319Y, N346H, and
C419F) in the laminin type VI domain of this protein
mark this region for a potentially significant functional
role in the cochlea and retina. Of particular interest are
the other classes of proteins containing domain VI mo-
tifs: laminin subunits a1, a2, a5, b1–b3, g1, g3, and
netrins. Laminins (reviewed in Timpl 1996) are the ma-
jor noncollagenous components of basement mem-
branes that mediate cell adhesion, growth, migration,
and differentiation. They function as heterotrimers
composed of a, b, and g subunits that combine to form
12 known heterotrimeric assembly forms, laminin-1
through -12 (Miner et al. 1997; Koch et al. 1999). Do-
main VI of the laminin subunits is crucial to a three-
arm interaction model in which individual laminin het-
erotrimers polymerize via calcium ion–dependent do-
main VI interactions into quasihexagonal networks
(Yurchenco and Cheng 1993). Netrins are small diffus-
able proteins that control guidance of central nervous
system commissural axons at the midline and peripheral
motor axons (reviewed in Tessier-Lavigne and Good-
man 1996). A homolog of netrin in C. elegans, UNC-
6, is one of the cues in the extracellular matrix that
guides dorsoventral migrations of pioneer axons and
migrating cells along the body wall on the epidermis
(Ishii et al. 1992). It has been proposed that netrins may
copolymerize within the laminin network in the base-
ment membrane via its domain VI (Wadsworth et al.
1996).
Several mutations in the domain VI region of the
genes encoding laminin subunits b3 (E210K), a2 (dy2J),
and the C. elegans netrin UNC-6 (ev437 and ev436hs)
have been shown (fig. 4). These mutations appear to
permit at least some protein translation, with the en-
coded proteins producing less-severe phenotypes than
null mutations. The mutation E210K, in the domain VI
of laminin b3, is predictive of a less severe, nonlethal
form of epidermolysis bullosa (MIM 226650; Mellerio
et al. 1998), a genetically heterogeneous group of dis-
eases characterized by easy blistering and fragility of the
skin, where mutations in the genes encoding various
components of the hemidesmosomal-anchoring fila-
ment complex and epidermal basement membrane have
been identified (Pulkkinen and Uitto 1999). Similarly,
mutations in laminin a2 and components of the dys-
trophin-associated glycoprotein complex cause various
forms of muscular dystrophy (Culligan et al. 1998). The
muscular dystrophy mouse dy2J produces a less severe
phenotype because of a 57-aa deletion within the do-
main VI of laminin a2 (Sunada et al. 1995). The altered
laminin-2 heterotrimer localizes to the basement
membrane but is defective in laminin polymerization
(Colognato et al. 1999). The UNC-6 mutations ev436hs
and ev437 cause the selective loss of some, but not all,
cell and axonal migrations directed by UNC-6 cues
(Wadsworth et al. 1996).
The less severe phenotypes associated with these do-
main VI mutants appear to be in contrast to those of
Usherin, in particular the C319Y homozygote. A review
of clinical records indicates that this individual is phe-
notypically indistinguishable from several 2299delG ho-
mozygotes. In this regard, the domain VI UNC-6 mu-
tation rh46 (A136P; fig. 4) produces a defective cell and
axonal migration phenotype indistinguishable from the
UNC-6 ev400 (Q78X) stop-codon mutant (Wadsworth
et al. 1996).
Although netrin and laminin subunits share domain
VI in commonwith Usherin, one difference is themotif’s
location in the protein. The domain VI in laminin sub-
units and netrin molecules is located at theNH2 terminal
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end of these proteins. In the case of Usherin, its domain
VI is preceded by ∼300 aa of novel sequence (fig. 3).
The potential functional role of Usherin in the devel-
opment or maintenance of the sensory systems of the
ear and eye based solely on domain structure similarities
with laminins and netrins would be speculative. Re-
cently, however, mutations in the human homolog of
the Drosophila melanogaster protein crumbs (CRB1)
have been identified in patients with a severe and specific
form of autosomal recessive RP (RP12 [MIM 600105])
on chromosome 1q31-32.1. The CRB1 protein, which
contains 19 EGF-like domains, three laminin A G-like
domains, and a C-type lectin domain, is implicated in
neuronal development of the retina; this fact is based
on domain similarities with other EGF-like domain-con-
taining proteins that are essential for neuronal devel-
opment (den Hollander et al. 1999). It is quite likely
that the mutated cysteine residues we have identified in
patients with USHIIa disrupt intra- or intermolecular
disulfide bonds. Whether these changes lead to an un-
stable protein more sensitive to proteolytic degradation
or to an alteration in the structure and thus function of
the protein is unknown. The identification of Usherin
protein-binding partners, its subcellular localization,
and its spatial and temporal pattern of expression will
provide the evidence for a model of the function of this
molecule in the cochlea and retina.
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